https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-27 / Cancers (Basel) 2022 Jan;14(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-27 / Cancers (Basel) 2022 Jan;14(3)2022-01-27 00:00:002024-02-05 11:28:29Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-24 / Exp Hematol Oncol 2022 Jan;11(1):3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-24 / Exp Hematol Oncol 2022 Jan;11(1):32022-01-24 00:00:002022-01-24 00:00:00Research progress on dendritic cell vaccines in cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-19 / Genes Immun 2022 02;23(1):1-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-19 / Genes Immun 2022 02;23(1):1-112022-01-19 00:00:002022-01-19 00:00:00Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-07 / J Healthc Eng 2022;2022:2518847
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-07 / J Healthc Eng 2022;2022:25188472022-01-07 00:00:002022-01-07 00:00:00GP96 and SMP30 Protein Priming of Dendritic Cell Vaccination Induces a More Potent CTL Response against Hepatoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-06 / Expert Rev Vaccines 2022 Mar;21(3):337-353
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-06 / Expert Rev Vaccines 2022 Mar;21(3):337-3532022-01-06 00:00:002022-01-06 00:00:00Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-01 / J Immunother Cancer 2022 Jan;10(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-01 / J Immunother Cancer 2022 Jan;10(1)2022-01-01 00:00:002022-01-01 00:00:00Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-01-01 / Integr Cancer Ther 2022;21:15347354221083968
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-01-01 / Integr Cancer Ther 2022;21:153473542210839682022-01-01 00:00:002023-03-22 14:40:49A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
